Perinatal EvidenceCompass
Prepopulated workbenchMED-238

Substance-use disorder — nicotine

Bupropion sustained-release (smoking cessation)

Smoking-cessation treatment; cross-reference antidepressant bupropion

Brand / product examples: Zyban · generics

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Bupropion sustained-release (smoking cessation)
Entity type
single-ingredient drug
Active component(s)
Bupropion hydrochloride
Formulation / route / interval
Oral sustained-release tablet
Attachment entry
Bupropion SR
Separate monograph status
Yes — indication/formulation-specific cross-reference
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

1 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-021Provisional public source

A 2025 multinational cohort found no clear overall major-congenital-malformation increase with first-trimester varenicline, bupropion or NRT compared with smoking, but it does not establish pregnancy cessation efficacy or exclude uncommon risks.

Public-source certainty descriptor
Moderate-low; large observational study
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
First trimester
Comparator
Cessation medicines versus smoking in pregnancy
Effect or numbers carried forward

No clear overall MCM elevation in studied exposure groups

Limitations

Residual confounding, adherence uncertainty and limited power for specific defects

Sources, citation controls, and verification state

Linked sources

PMID
40163085
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending